# S. Harvey Mudd

| Key fact | Detail |
|---|---|
| Signature work | "Folate-Responsive Homocystinuria and 'Schizophrenia'", New England Journal of Medicine, 1975<sup>[2](https://doi.org/10.1056/nejm197503062921001)</sup> |
| Landmark findings | Enzymatic defect in homocystinuria (Science, 1964); sulfite oxidase deficiency in man (Science, 1967)<sup>[3](https://doi.org/10.1126/science.143.3613.1443)</sup><sup> • </sup><sup>[4](https://doi.org/10.1126/science.156.3782.1599)</sup> |

## Early life and training

The "S." that begins S. Harvey Mudd's name was a deliberate signature. 

In 1953 Mudd received his M.D. from Harvard and completed an internship at [Massachusetts General Hospital](https://www.edgepedia.org/massachusetts-general-hospital).<sup>[1](https://d.docksci.com/in-memoriam-s-harvey-mudd_5a577f95d64ab2a658512a02.html)</sup>

## Research on homocystinuria and sulfur metabolism

Homocystinuria is a disorder in which homocysteine, an intermediate of methionine metabolism, accumulates in blood and urine. A deficiency of the enzyme cystathionine beta-synthase is its most common cause.<sup>[5](https://www.ncbi.nlm.nih.gov/books/NBK28195/)</sup> In 1964 a Science paper from Mudd's group demonstrated a deficiency or absence of cystathionine synthetase activity in liver obtained from a mentally retarded child with homocystinuria, converting a clinical syndrome into a defined enzymatic defect.<sup>[3](https://doi.org/10.1126/science.143.3613.1443)</sup>

According to Mudd's 1967 Science paper on sulfite oxidase deficiency, an infant died with neurological abnormalities, mental retardation, and dislocated ocular lenses, excreting abnormally large amounts of S-sulfo-L-cysteine, sulfite, and thiosulfate with virtually no inorganic sulfate. The infant's liver, brain, and kidney specifically lacked sulfite oxidase activity, an enzymatic defect not apparently previously described in man.<sup>[4](https://doi.org/10.1126/science.156.3782.1599)</sup>

The 1970 work showed that a class of patients with cystathionine beta-synthase deficiency could be successfully treated with pharmacological amounts of the enzyme's cofactor, vitamin B6.<sup>[1](https://d.docksci.com/in-memoriam-s-harvey-mudd_5a577f95d64ab2a658512a02.html)</sup>

A paper published in the New England Journal of Medicine in 1975 examined a patient whose homocystinuria responded to folate and who carried a psychiatric diagnosis. It demonstrated a defect in the ability to reduce N-5-10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, with methylenetetrahydrofolate reductase measured at 18 per cent of control values.<sup>[2](https://doi.org/10.1056/nejm197503062921001)</sup>

## Representative work

The 1975 New England Journal of Medicine paper "Folate-Responsive Homocystinuria and 'Schizophrenia'" demonstrated a defect in the ability to reduce N-5-10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, with methylenetetrahydrofolate reductase activity at 18 per cent of control values, in a patient whose homocystinuria responded to folate.<sup>[2](https://doi.org/10.1056/nejm197503062921001)</sup> 

## Legacy and current practice

Current guidance lists vitamin B6 for responsive patients, a methionine-restricted diet, folic acid, and vitamin B12 supplementation as needed, and betaine, a methyl donor that remethylates homocysteine.<sup>[6](https://www.ncbi.nlm.nih.gov/books/NBK1524/)</sup> According to Orphanet, the same three modalities are described, with pyridoxine given in pharmacological doses up to a maximum of 500 mg/day.<sup>[7](https://www.orpha.net/en/disease/detail/394?mode=name)</sup> In adolescents and adults betaine may be the major treatment, though a life-long methionine-restricted diet is preferable, and in patients who have already had a vascular event betaine alone may prevent recurrences.<sup>[6](https://www.ncbi.nlm.nih.gov/books/NBK1524/)</sup> Guideline dosing begins at 50 mg/kg twice daily for children and 3 grams twice daily for adults.<sup>[8](https://link.springer.com/article/10.1007/s10545-016-9979-0)</sup>

How common the condition is remains unsettled. One guideline reports estimates from 1:1,800 to 1:900,000 depending on ascertainment,<sup>[8](https://link.springer.com/article/10.1007/s10545-016-9979-0)</sup> and GeneReviews states that the estimated prevalence in Qatar, 1:1,800 in a study of newborns, may be the highest in the world.<sup>[6](https://www.ncbi.nlm.nih.gov/books/NBK1524/)</sup> A newborn-screening review estimates 1:344,000 worldwide while molecular studies predict 1:6,400 to 1:20,500 in European populations.<sup>[9](https://link.springer.com/article/10.1007/s10545-015-9830-z)</sup>

For sulfite oxidase deficiency, there is no effective treatment and management is supportive, with a low-sulfur diet possibly helpful in milder molybdenum cofactor deficiency.<sup>[10](https://www.msdmanuals.com/professional/pediatrics/inherited-disorders-of-metabolism/methionine-metabolism-disorders)</sup> [Molybdenum cofactor deficiency](https://www.edgepedia.org/molybdenum-cofactor-deficiency) type A has recently become amenable to causal treatment with synthetic cPMP (fosdenopterin), although the evidence base for its rational use is very limited.<sup>[11](https://onlinelibrary.wiley.com/doi/10.1002/jimd.12730)</sup>
## References

1. In Memoriam: S. Harvey Mudd. *American Journal of Medical Genetics Part A*, 2015. https://d.docksci.com/in-memoriam-s-harvey-mudd_5a577f95d64ab2a658512a02.html
2. Folate-Responsive Homocystinuria and "Schizophrenia". *New England Journal of Medicine*, 1975. https://doi.org/10.1056/nejm197503062921001
3. Homocystinuria: An Enzymatic Defect. *Science*, 1964. https://doi.org/10.1126/science.143.3613.1443
4. Sulfite Oxidase Deficiency in Man: Demonstration of the Enzymatic Defect. *Science*, 1967. https://doi.org/10.1126/science.156.3782.1599
5. Sulfur Amino Acid Metabolism: Homocystinuria. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK28195/
6. Homocystinuria Due to Cystathionine Beta-Synthase Deficiency. GeneReviews. https://www.ncbi.nlm.nih.gov/books/NBK1524/
7. Homocystinuria due to cystathionine beta-synthase deficiency. Orphanet. https://www.orpha.net/en/disease/detail/394?mode=name
8. Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency. *Journal of Inherited Metabolic Disease*, 2017. https://link.springer.com/article/10.1007/s10545-016-9979-0
9. Newborn screening for homocystinurias and methylation disorders. *Journal of Inherited Metabolic Disease*, 2017. https://link.springer.com/article/10.1007/s10545-015-9830-z
10. Methionine Metabolism Disorders. MSD Manual Professional Edition. https://www.msdmanuals.com/professional/pediatrics/inherited-disorders-of-metabolism/methionine-metabolism-disorders
11. Consensus guidelines for the diagnosis and management of isolated sulfite oxidase deficiency and molybdenum cofactor deficiencies. *Journal of Inherited Metabolic Disease*, 2024. https://onlinelibrary.wiley.com/doi/10.1002/jimd.12730

---
*Topic: Encyclopedia › Life and health › Life and health scientists › Medical and health researchers › Medical genetics researchers*

*Initially written Sep 21, 2026 · Reviewed: Sep 25, 2026 · Edited: Sep 25, 2026; Oct 15, 2026 · Last review: Sep 25, 2026*

*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*

License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license
